| Name | Title | Contact Details |
|---|---|---|
Jacqui Boire |
Director, Technology Strategy and Planning | Profile |
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. With a reputation for scientific and technical excellence, combined with a passion for delivering quality products on time, every time, our approximately 8,700 employees across North America, Europe, Latin America and Australia have enabled Patheon to achieve industry-leading growth. When you join Patheon, you are joining a team that is dedicated to transforming an industry and advancing our clients’ successes, today and tomorrow. Every day, our teams seek out opportunities for operational improvements across the enterprise to ensure we can deliver medicines that are right the first time and on time, while continually working to simplify the supply chain process and focus on what’s next by optimizing our offerings in innovative ways.
Champions Oncology is a company that develops technology solutions and services for personalizing the development and use of oncology drugs. Their technology-enabled research platforms empower biopharma to create a comprehensive understanding of tumor ...
We are completely committed to the success of every one of our client-partners and dedicate ourselves to quality and efficiency. We provide custom formulation and quality manufacturing for your existing formulas and welcome the opportunity to provide
UPM Pharmaceuticals is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.